As of late 2024, Andrew Guggenhime has actively traded Vaxcyte's common stock, reflecting a strong commitment to the company's future. His insider trading activity shows significant investment fluctuations, peaking in 2024 with a month where he sold over $10.19 million...

As of late 2024, Andrew Guggenhime has actively traded Vaxcyte's common stock, reflecting a strong commitment to the company's future. His insider trading activity shows significant investment fluctuations, peaking in 2024 with a month where he sold over $10.19 million worth of stock. This followed a trend that began substantially in 2021, where he made trades ranging from $66.96K to upwards of $1.75 million. The pattern of increasing sales showcases a gain not only in stock price but also a confidence in the direction of Vaxcyte's pipeline and earnings potential. His current holding indicates a noteworthy investment of approximately $532,221, which represents about 1% of total shares owned by insiders—an essential stake indicating trust in the company's direction and performance.